Jakafi sales october 2025?

Information regarding Jakafi sales specifically for October 2025 is not yet available. Drug sales figures are typically reported retrospectively on a quarterly or annual basis.

When Does Jakafi's Patent Protection End?

The patent expiry for Jakafi (ruxolitinib) is a key factor influencing its future market availability and sales. According to DrugPatentWatch.com, Jakafi is protected by several patents, with varying expiry dates [1]. The ultimate expiry of its primary patent protection will allow for the potential introduction of generic versions of the drug.

How Are Jakafi Sales Performing Currently?

Jakafi has demonstrated significant sales performance. In the first quarter of 2024, the drug generated approximately $677 million in net sales [2]. This indicates a strong market presence and demand for the medication.

What Are the Next Steps for Jakafi?

Jakafi is approved for several indications, including myelofibrosis, polycythemia vera, and graft-versus-host disease [3]. Ongoing clinical trials continue to explore its efficacy in new therapeutic areas and patient populations, which could further impact its sales trajectory and market reach in the future.